The Clinical Research Gold Rush
Something unusual is happening in clinical research, and most founders and investors are underestimating it.
On the surface, 2026 looks like a “recovery year” for biotech and pharma. Beneath that, however, lies a structural reset in how drugs are discovered, developed, and commercialized. Resets like this don’t just create growth—they create strategic M&A opportunities that can define the next decade (Deloitte US, 2026; Deloitte US Center for Health Solutions, 2025).
If you’re a founder, investor, or operator in clinical research, this is the moment to pay attention.
The global contract research organization (CRO) market is on a significant growth trajectory, projected to expand from around $56.6B in 2025 to over $96B by 2035, reflecting a ~5.44% CAGR (Precedence Research, 2025).
What’s really happening goes beyond simple supply growth:
CROs are no longer just vendors, they are becoming strategic infrastructure, and infrastructure, tends to consolidate.
After a cautious and deal-constrained 2025, life sciences M&A rebounded strongly. Deloitte reported ~$220B in life sciences M&A through late 2025, led by pharma deals and targeted bolt‑on strategies (Deloitte US, 2026).
Strategic buyers aren’t just acquiring pipelines, they’re acquiring capabilities across the clinical value chain. Patient recruitment platforms, decentralized trial technologies, regulatory and data infrastructure, and specialized CRO niches are all active acquisition targets. This is not a pipeline grab, it is a full-scale platform land grab (PwC, 2026; Deloitte US, 2026). In other words, this is no longer just a race to acquire medicine pipelines, it is a race to build and acquire the platforms that drive clinical development and maximize strategic returns.
Clinical development in 2026 is no longer linear, it is modular, fragmented, and rapidly evolving. Three forces are driving this transformation:
The intersection of fragmentation and strategic demand is creating a rare window for buyers and sellers:
The most valuable targets are strategically positioned, not just large. Buyers are focused on:
Anything that can de-risk, accelerate, or scale clinical development is in demand.
Valuation has shifted. It is no longer just about revenue or EBITDA, it is about positioning within the clinical ecosystem. In this environment, the gap between an average outcome and a premium exit is defined by where, and how, you fit.
The rules of value creation are being rewritten in real time (Deloitte, 2025a; PwC, 2026).
The companies that act now will help define the next decade of clinical development. Buyers are active, capital is available, and competition for the right assets is intensifying.
Whether you’re exploring a sale, recapitalization, or acquisition strategy, timing and positioning matter more than ever. Buyers are active, capital is available, and competition for the right assets is intensifying.
The clinical research gold rush has already started. The question is—are you on the right side of it?
Contact Us
Our team can help you navigate every part of this journey. At Evergreen M&A, we’ve guided numerous clinical research exits and acquisitions, helping founders and investors capture maximum value in a rapidly consolidating market.
If you’d like to learn more about the current M&A market for clinical research, feel free to reach out to Managing Director, Hannah Huke, at hannah@evergreenforfounders.com.
Contact us today to explore how you can monetize this structural shift.